Head-to-head · Cost-Efficiency Index
Hims & Hers vs Henry Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Hims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersHenry Meds
People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Visit Henry MedsThe verdict
Hims & Hers takes it, leading the Cost-Efficiency Index 83 to 81. Nationwide reach and a slick app at a mid-market semaglutide price — but an undisclosed tirzepatide price leaves part of the value equation blank. Henry Meds still earns a B− — People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Hims & Hers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Hims & Hers | Henry Meds |
|---|---|---|
| Cost-Efficiency Index | 83/100 | 81/100 |
| Semaglutide / mo | $199/mo | $249/mo |
| Tirzepatide / mo | Not disclosed | $349/mo |
| Semaglutide / yr (modeled) | $2,388 | $2,988 |
| Tirzepatide / yr (modeled) | — | $4,188 |
| Coverage | All 50 states | Multi-state |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #22 | #28 |
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Henry Meds
81/100Where the value is
- Simple, transparent flat-fee model that's easy to model
- Well-established brand
- Both molecules disclosed
The tradeoffs
- Higher per-month cost than many newer entrants weakens value
- Compounded only
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.